Among patients eligible for MBS, GLP-1 RA prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023.

Implementation of an OPTN wait-time modification policy in 2023 was associated with increased kidney transplant rates among Black patients.

Poor childhood oral health is associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD) in adulthood.

The AHA predicts that total cardiovascular disease burden among US women will rise from 10.7% to 14.4% by 2050, driven by aging and diversity.

GLP-1 RAs for weight loss appear to be similarly effective among adults across ages, races, and starting weights.

The SMART2 model effectively estimates 10-year recurrent CV risk in stable patients but may underestimate risk in certain vulnerable populations.

The AHA released a statement for malnutrition and cachexia in patients with cardiac conditions, and discuss clinical strategies for support and management.

Twenty percent of potentially eligible youth are prescribed GLP-1 RAs, with the odds of prescription higher with increasing ...

The ACC and AHA released updated guidelines for the management of dyslipidemia to reduce risk for atherosclerotic cardiovascular disease.

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs does not increase risks for thrombosis or bleeding.